Our own cloning efforts are still associated with shortened telomeres because we haven’t found the reset but this is an issue that doesn’t exist with starfish reproduction and limb regeneration.
In long-awaited and landmark study published yesterday in Genetics, Lapham and 28 other authors collaborated to report telomere length in a cohort of Kaiser patients who gave saliva samples.
After two years of TA-65 use, his median length is now 12,500 (from an estimated 9,400) with a very nice drop in critically-short telomeres to 4.5% (from a baseline of up to 20%). So if you believe what most research is showing regarding the connection between shorter telomeres and longevity, Mark has gained over 30 years of longevity in a time where he should have lost three years.
Men who developed cancers were compared with those that didn’t for the 13 years prior to diagnosis or exclusion by using a quantitative PCR measurement (which is problematic). Firstly, they found was two different curves with the cancer group showing a more rapid shortening trend. This is consistent with my stem cell theory of aging and most of the extant studies.
When data from the Copehnhagen City Heart Study was published in 2013, they concluded that shorter telomeres in leukocytes was not associated with increased cancer after adjusting for age but that it WAS associated with reduced survival from cancer http://jnci.oxfordjournals.org/content/105/7/459.long
In 2015, the same data looked at certain gene tendencies that promote telomere shortening and concluded that cancer survival was IMPROVED when shortening was enhanced in the telomeres.
Contradiction? Not so fast.
Just a brief video showing an illustration of how telomerase works. I don’t believe there is an “End replication problem” as such because you want the non-stem cell ends to erode in the less valuable, differentiated and mortal cells. They are like drone bees that last months, unlike the queen bee stem cells which last years
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
